Literature DB >> 23908110

A leader sequence capable of enhancing RNA expression and protein synthesis in mammalian cells.

Brian P Wellensiek1, Andrew C Larsen, Julia Flores, Bertram L Jacobs, John C Chaput.   

Abstract

Many applications in biotechnology require human proteins generated from human cells. Stable cell lines commonly used for this purpose are difficult to develop, and scaling to large numbers of proteins can be problematic. Transient expression can circumvent this problem, but protein yields are generally too low for most applications. Here we report a novel 37-nucleotide leader sequence that promotes rapid and high transgene expression in mammalian cells. This sequence was identified by in vitro selection and functions in a transient vaccinia-based cytoplasmic expression system. Vectors containing this sequence produce microgram levels of protein in just 6 h from a small-scale expression in 10(6) cells. This level of protein synthesis is ideal for high throughput production of human proteins, and could be scaled to generate milligram quantities of protein. The technology is compatible with a broad range of cell lines, accepts plasmid and linear DNA, and functions with viruses that are approved for use under BSL1 conditions. We suggest that these advantages provide a powerful method for generating human protein in mammalian cells.
© 2013 The Protein Society.

Entities:  

Keywords:  human vaccinia virus; mammalian cell culture; recombinant protein synthesis; translation enhancing elements

Mesh:

Substances:

Year:  2013        PMID: 23908110      PMCID: PMC3795497          DOI: 10.1002/pro.2325

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  16 in total

Review 1.  Production of recombinant protein therapeutics in cultivated mammalian cells.

Authors:  Florian M Wurm
Journal:  Nat Biotechnol       Date:  2004-11       Impact factor: 54.908

2.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

Authors:  T R Fuerst; E G Niles; F W Studier; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

Review 3.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

Review 4.  Mammalian cell protein expression for biopharmaceutical production.

Authors:  Jianwei Zhu
Journal:  Biotechnol Adv       Date:  2011-09-24       Impact factor: 14.227

5.  Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.

Authors:  I Drexler; K Heller; B Wahren; V Erfle; G Sutter
Journal:  J Gen Virol       Date:  1998-02       Impact factor: 3.891

Review 6.  Transfer and expression of foreign genes in mammalian cells.

Authors:  A Colosimo; K K Goncz; A R Holmes; K Kunzelmann; G Novelli; R W Malone; M J Bennett; D C Gruenert
Journal:  Biotechniques       Date:  2000-08       Impact factor: 1.993

Review 7.  Recombinant expression systems in the pharmaceutical industry.

Authors:  F R Schmidt
Journal:  Appl Microbiol Biotechnol       Date:  2004-07-24       Impact factor: 4.813

Review 8.  Production of recombinant proteins by microbes and higher organisms.

Authors:  Arnold L Demain; Preeti Vaishnav
Journal:  Biotechnol Adv       Date:  2009-01-31       Impact factor: 14.227

Review 9.  Human cells: new platform for recombinant therapeutic protein production.

Authors:  Kamilla Swiech; Virgínia Picanço-Castro; Dimas Tadeu Covas
Journal:  Protein Expr Purif       Date:  2012-05-11       Impact factor: 1.650

10.  A translation initiation element specific to mRNAs with very short 5'UTR that also regulates transcription.

Authors:  Rofa Elfakess; Rivka Dikstein
Journal:  PLoS One       Date:  2008-08-28       Impact factor: 3.240

View more
  4 in total

Review 1.  Non-viral therapeutic approaches to ocular diseases: An overview and future directions.

Authors:  Rahel Zulliger; Shannon M Conley; Muna I Naash
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

2.  Development of a full-length human protein production pipeline.

Authors:  Justin Saul; Brianne Petritis; Sujay Sau; Femina Rauf; Michael Gaskin; Benjamin Ober-Reynolds; Irina Mineyev; Mitch Magee; John Chaput; Ji Qiu; Joshua LaBaer
Journal:  Protein Sci       Date:  2014-06-02       Impact factor: 6.725

3.  Computational Inference, Validation, and Analysis of 5'UTR-Leader Sequences of Alleles of Immunoglobulin Heavy Chain Variable Genes.

Authors:  Yixun Huang; Linnea Thörnqvist; Mats Ohlin
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

4.  Exploring the Role of AUG Triplets in Human Cap-Independent Translation Enhancing Elements.

Authors:  Amber N Juba; John C Chaput; Brian P Wellensiek
Journal:  Biochemistry       Date:  2018-10-29       Impact factor: 3.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.